O

ne of India’s largest drug makers has run afoul of US regulators for a plethora of serious violations that include improperly destroying documents, failing to follow procedures for preventing bacterial contamination, and maintaining incomplete lab records.

In a Dec. 23 warning letter, the US Food and Drug Administration cited extensive problems found at a facility run by Wockhardt, which makes numerous medicines for India’s domestic market as well as generics sold in other countries. The missive, which was posted on the agency web site on Tuesday, described problems that were found during an FDA inspection in late 2015.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy